Antisoma licenses rights to develop Betagenon's AMPK activators as cancer treatments
On April 14, 2008, Cancer drug developer Antisoma plc acquired a licence from Betagenon AB, a privately held Swedish biotechnology company, to develop and commercialise Betagenon's AMPK activators in cancer indications.
Antisoma was advised by Gary Howes of Fasken Martineau Stringer Saul.